ROCKVILLE, MD – June 10, 2021 – DP Clinical, Inc., a Contract Research Organization (CRO) specializing in dermatology, infectious disease, neuroscience, oncology, and ophthalmology Phase I-III clinical programs; continues its growth with the addition of Tim Urschel as Vice President, Regulatory Affairs/Quality Assurance. Mr. Urschel joined the DP Clinical team in October 2020 and brings more than 25 years of experience in regulatory affairs and GxP quality assurance including regulatory GxP compliance and development of quality management systems in both GCP and GMP environments. His broad range of experience includes the development of regulatory strategies including NDAs, INDs, Annual Reports, Orphan Drug Applications, CTAs, and MAA applications.

Prior to joining DP Clinical, Mr. Urschel worked for Onconova Therapeutics, Inc. as a Vice President, Quality Assurance, where he was responsible for the overall quality assurance function to ensure compliance with federal and local regulations using a risk-based approach.

Mr. Urschel holds a BS degree in Medicinal Chemistry from the State University of New York at Buffalo and an MBA in Pharmaceutical Studies from Fairleigh-Dickinson University, Rutherford, New Jersey, and is a certified Quality Assurance Professional from the Society of Quality Assurance (SQA), an Accredited Clinical Researcher.

“Tim has touched every aspect of clinical research working at CROs, biotech, and pharmaceutical companies and is a proven leader in managing and building regulatory affairs and quality assurance functions in a competitive industry. We are excited to have him spearhead this initiative at DP Clinical,” stated Devinder Poonian, President and CEO.